<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418714</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00131537</org_study_id>
    <secondary_id>5R01DA003889-31</secondary_id>
    <nct_id>NCT03418714</nct_id>
  </id_info>
  <brief_title>Effects of Salvinorin A on Brain Function</brief_title>
  <official_title>Effects of Salvinorin A on Brain Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of salvinorin A on human brain activity and&#xD;
      connectivity using functional magnetic resonance imaging (fMRI) methods. An inhalation route&#xD;
      of administration will be used as it is the most common route for contemporary use of Salvia&#xD;
      divinorum, a plant containing salvinorin A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Volunteers will undergo two experimental sessions that include the inhalation of salvinorin&#xD;
      A. The first session will be completed in a comfortable space furnished as a living room, and&#xD;
      the second session will be conducted within a magnetic resonance imaging (MRI) scanner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">March 2, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participants will not be aware of exact doses salvinorin A (i.e. they will be told they may receive placebo or up to a moderately high dose of of salvinorin A).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Brain Activity (fMRI) as Assessed by Variance in BOLD Signal</measure>
    <time_frame>Pre salvinorin A administration and 20 minutes post-salvinorin A administration</time_frame>
    <description>Changes in brain activity from before to after salvinorin A administration within canonical brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), and lateral visual or (LatV)] will be assessed using blood-oxygenation level dependent (BOLD) techniques. Due to salvinorin A's potential confounding influence on blood flow, activity was assessed by looking at the variance in the BOLD signal. Variance in BOLD signal is a dimensionless variable that can vary from 0 to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Brain Connectivity (fMRI) as Assessed by Pearson's Correlation</measure>
    <time_frame>Pre-salvinorin A administration and 20 minutes post-salvinorin A administration</time_frame>
    <description>Changes in within and between network functional connectivity (FC) from pre to post-salvinorin A (SA) administration in several brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), lateral visual or (LatV)] is assessed via analysis of blood-oxygenation level dependent (BOLD) data. FC is the association between the BOLD activity of two regions over time. This is measured with a Pearson's correlation that is made parametric via z-transformation. FC within a network is the average of all possible pairwise combinations of z-transformed correlations within a network. FC between two networks is the average of all possible pairwise combinations of z-transformed correlations between two networks. We looked at the change in FC from pre to post-SA averaged across participants (this also gives a measure of dispersion).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>Salvinorin A administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All volunteers will be assigned to the salvinorin A administration arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvinorin A</intervention_name>
    <description>Salvinorin A, blinded doses</description>
    <arm_group_label>Salvinorin A administration</arm_group_label>
    <other_name>salvia, salvia divinorum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
          -  Have a high school level of education&#xD;
&#xD;
          -  Have a history of hallucinogen use and experience with an inhaled psychoactive drug.&#xD;
&#xD;
          -  Recent experience (within the past year) with an inhaled psychoactive drug.&#xD;
&#xD;
          -  Agree to consume approximately the same amount of caffeine-containing beverage (e.g.,&#xD;
             coffee, tea) that he/she consumes on a usual morning, before arriving at the research&#xD;
             unit on the mornings of drug session days. If the volunteer does not usually consume&#xD;
             caffeinated beverages, he or she must agree not to do so on session days&#xD;
&#xD;
          -  Agree to refrain from using any psychoactive drugs, including alcoholic beverages and&#xD;
             any tobacco product such as cigarettes or any other nicotine product such as&#xD;
             e-cigarettes, within 24 hours of each drug administration. Exceptions include daily&#xD;
             use of caffeine.&#xD;
&#xD;
          -  Be healthy and psychologically stable as determined by screening for medical problems&#xD;
             via a personal interview, a medical questionnaire, a physical examination, and routine&#xD;
             medical blood and urinalysis laboratory tests&#xD;
&#xD;
          -  Agree that for one week before each session, he/she will refrain from taking any&#xD;
             nonprescription medication, nutritional supplement, or herbal supplement except if&#xD;
             approved by the study investigators. Exceptions will be evaluated by the study&#xD;
             investigators and will include acetaminophen, non-steroidal anti-inflammatory drugs,&#xD;
             and common doses of vitamins and minerals&#xD;
&#xD;
          -  Agree not to take any Pro-re-nata (PRN) prescription medications on the mornings of&#xD;
             the sessions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant (as indicated by a positive urine pregnancy test assessed at&#xD;
             intake and before each drug session) or nursing; women who are of child-bearing&#xD;
             potential and sexually active who are not practicing an effective means of birth&#xD;
             control&#xD;
&#xD;
          -  Cardiovascular conditions: coronary artery disease, stroke, angina, uncontrolled&#xD;
             hypertension, or Transient Ischemic Attack (TIA) in the past year&#xD;
&#xD;
          -  Seizure disorder or epilepsy with history of seizures&#xD;
&#xD;
          -  Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of&#xD;
             hypoglycemia&#xD;
&#xD;
          -  Currently taking psychoactive prescription medication on a regular (e.g., daily) basis&#xD;
&#xD;
          -  More than 25% outside the upper or lower range of ideal body weight&#xD;
&#xD;
          -  Current or past history of meeting Diagnostic and Statistical Manual (DSM)-V criteria&#xD;
             for schizophrenia, psychotic disorder (unless substance-induced or due to a medical&#xD;
             condition), dissociative disorder, bipolar I or II disorder, an eating disorder&#xD;
&#xD;
          -  Current or past history of substance-induced psychosis.&#xD;
&#xD;
          -  Current or past history within the last 2 years of meeting DSM-5 criteria for moderate&#xD;
             or severe alcohol or substance use disorder (excluding caffeine)&#xD;
&#xD;
          -  Daily or more frequent tobacco or nicotine use&#xD;
&#xD;
          -  Current severe obsessive-compulsive disorder, dysthymic disorder, or panic disorder.&#xD;
&#xD;
          -  Current, severe, major depression&#xD;
&#xD;
          -  Have a first or second degree relative with schizophrenia, psychotic disorder (unless&#xD;
             substance induced or due to a medical condition), or bipolar I or II disorder&#xD;
&#xD;
          -  Has a psychiatric condition judged to be incompatible with establishment of rapport or&#xD;
             safe exposure to salvinorin A&#xD;
&#xD;
          -  Head trauma, traumatic brain injury, or concussion with loss of consciousness for &gt;2&#xD;
             minutes&#xD;
&#xD;
          -  Claustrophobia incompatible with MRI scanning&#xD;
&#xD;
          -  Medical device incompatible with MRI scanning (e.g. cardiac pacemaker, implanted&#xD;
             cardiac defibrillator, aneurysm brain clip, inner ear implant)&#xD;
&#xD;
          -  Prior history as a metal worker and/or certain metallic objects in the body -- must&#xD;
             complete MRI screening form and be approved by MRI technologist before each scan&#xD;
&#xD;
          -  Left-handedness (assessed by the Edinburgh Handedness Inventory)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick S Barrett, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.drugalcdep.2010.11.005</url>
    <description>Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>February 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2021</results_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salvinorin A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03418714/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Salvinorin A Administration</title>
          <description>All volunteers will be assigned to the salvinorin A administration arm.&#xD;
Salvinorin A: Salvinorin A (15 micrograms/kg, vaporized), blinded doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">One participant moved too much during the practice session and was therefore excluded from the scan.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Salvinorin A Administration</title>
          <description>All volunteers will be assigned to the salvinorin A administration arm.&#xD;
Salvinorin A: Salvinorin A, blinded doses</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.46" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime uses of Salvia divinorum</title>
          <description>Number of times Salvia divinorum (plant containing salvinorin A) had been used prior to participating in the study.</description>
          <units>number of times</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.08" spread="48.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Brain Activity (fMRI) as Assessed by Variance in BOLD Signal</title>
        <description>Changes in brain activity from before to after salvinorin A administration within canonical brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), and lateral visual or (LatV)] will be assessed using blood-oxygenation level dependent (BOLD) techniques. Due to salvinorin A's potential confounding influence on blood flow, activity was assessed by looking at the variance in the BOLD signal. Variance in BOLD signal is a dimensionless variable that can vary from 0 to infinity.</description>
        <time_frame>Pre salvinorin A administration and 20 minutes post-salvinorin A administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salvinorin A Administration</title>
            <description>All volunteers will be assigned to the salvinorin A administration arm.&#xD;
Salvinorin A: Salvinorin A, blinded doses</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain Activity (fMRI) as Assessed by Variance in BOLD Signal</title>
          <description>Changes in brain activity from before to after salvinorin A administration within canonical brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), and lateral visual or (LatV)] will be assessed using blood-oxygenation level dependent (BOLD) techniques. Due to salvinorin A's potential confounding influence on blood flow, activity was assessed by looking at the variance in the BOLD signal. Variance in BOLD signal is a dimensionless variable that can vary from 0 to infinity.</description>
          <units>variance in BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MF activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.65" spread="74.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.06" spread="117.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.39" spread="229.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.93" spread="40.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.06" spread="79.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedV activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.15" spread="406.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OccP activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.96" spread="366.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LatV activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="77.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>T test on the change in network activity across all networks, from before to after salvinorin A administration.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Brain Connectivity (fMRI) as Assessed by Pearson's Correlation</title>
        <description>Changes in within and between network functional connectivity (FC) from pre to post-salvinorin A (SA) administration in several brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), lateral visual or (LatV)] is assessed via analysis of blood-oxygenation level dependent (BOLD) data. FC is the association between the BOLD activity of two regions over time. This is measured with a Pearson's correlation that is made parametric via z-transformation. FC within a network is the average of all possible pairwise combinations of z-transformed correlations within a network. FC between two networks is the average of all possible pairwise combinations of z-transformed correlations between two networks. We looked at the change in FC from pre to post-SA averaged across participants (this also gives a measure of dispersion).</description>
        <time_frame>Pre-salvinorin A administration and 20 minutes post-salvinorin A administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salvinorin A Administration</title>
            <description>All volunteers will be assigned to the salvinorin A administration arm.&#xD;
Salvinorin A: Salvinorin A, blinded doses</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain Connectivity (fMRI) as Assessed by Pearson's Correlation</title>
          <description>Changes in within and between network functional connectivity (FC) from pre to post-salvinorin A (SA) administration in several brain networks [medial frontal (MF), frontoparietal (FP), default mode (DM), subcortical-cerebellum (SubC), somatosensory-motor (SM), medial visual (MedV), occipital pole (OccP), lateral visual or (LatV)] is assessed via analysis of blood-oxygenation level dependent (BOLD) data. FC is the association between the BOLD activity of two regions over time. This is measured with a Pearson's correlation that is made parametric via z-transformation. FC within a network is the average of all possible pairwise combinations of z-transformed correlations within a network. FC between two networks is the average of all possible pairwise combinations of z-transformed correlations between two networks. We looked at the change in FC from pre to post-SA averaged across participants (this also gives a measure of dispersion).</description>
          <units>Z-transformed Pearson's correlation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MF within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedV within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".06" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OccP within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LatV within-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-FP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-DM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-SubC between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".00" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-SM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-MedV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MF-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-DM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-SubC between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-SM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-MedV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FP-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM-SubC between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM-SM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM-MedV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DM-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC-SM between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".00" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC-MedV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SubC-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM-MedV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SM-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".01" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedV-OccP between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".02" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MedV-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".06" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OccP-LatV between-network connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>T test on the change in within- and between-network connectivity across all values, from before to after salvinorin A administration.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Salvinorin A Administration</title>
          <description>All volunteers will be assigned to the salvinorin A administration arm.&#xD;
Salvinorin A: Salvinorin A, blinded doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frederick Barrett</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4105509777</phone>
      <email>fbarret2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

